Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAFFR-CAR T cells in r/r B-ALL
NCT04690595Phase 1Active, not recruiting
- Sponsor
- PeproMene Bio, Inc.
- Start
- May 2021
- Primary completion
- Nov 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PMB-101 in acute lymphoblastic leukemia (ALL), sponsored by PeproMene Bio, Inc. Primary endpoint: Incidence of adverse events at 1 year. Started May 2021; status: active, not recruiting.
02
Drugs
PMB-101
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04690595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690595.